Edited by Kerry J. Ressler, Daniel S. Pine, and Barbara Olasov Rothbaum
Reviews and Awards
"All clinicians and clinical scientists working in anxiety disorders who would like a vision of where the field will be in 5 to 10 years should read this Primer. With three of the leading clinical investigators in the world as Editors, and with a first-rate roster of contributors covering all the latest findings from neurotransmitter underpinnings of drug treatments to the neuroscience of psychological treatments, readers can preview likely changes in diagnosis, assessment, and treatment in the years to come. Most importantly, we get a glimpse of a future in which we can individualize treatment based on a sound set of scientifically validated predictors of outcome. A must read!" - David H. Barlow PhD, ABPP, Professor of Psychology and Psychiatry, Boston University, Founder and Director Emeritus, Center for Anxiety and Related Disorders, Boston, MA"
"The study of anxiety, once the foundational concept for all psychopathology, maps the path for the future of all psychiatric neuroscience and psychobiology, revealing the rich interplay of nature, nurture and development, and yielding therapeutic advances in psychotherapies, psychopharmacology and neurotherapeutics. The publishers, editors and authors of this volume, and the pioneering organization that has brought them together, the ADAA, have delivered a comprehensive, essential and useful volume for the field." - Jerrold F. Rosenbaum, MD, Chief of Psychiatry, Massachusetts General Hospital; Stanley Cobb Professor of Psychiatry, Harvard Medical School, Boston, MA"
"Among the book's many strengths are its readability, the focus on the important, need-to-know material, and comprehensive summaries of cited research." - Doody's Notes